Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study
Miguel García‐Grimshaw, Santa Elizabeth Ceballos‐Liceaga, Anaclara Michel‐Chávez, Mario García-Alanis, Arturo Cadena‐Fernández, Javier Andrés Galnares‐Olalde, Guillermo Carbajal‐Sandoval, Daniel Amado Carrillo-García, Noé Hernández-Valdivia, Laura E. Hernández‐Vanegas, María del Mar Saniger‐Alba, Alonso Gutiérrez‐Romero, José Luis Díaz‐Ortega, Gustavo Reyes‐Terán, Hugo López‐Gatell, Fernando Flores-Silva, Carlos Cantú‐Brito, Erwin Chiquete, Antonio Araúz, Sergio Iván Valdés‐Ferrer
Topics & Concepts
ReactogenicityMedicineAdverse effectCoronavirus disease 2019 (COVID-19)ImmunizationCohortSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineImmunologyAntibodyDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyPsychology of Moral and Emotional Judgment